吴仁毅青光眼诊治新进展.ppt

青光眼诊治新进展及共识 浙江大学医学院附属第二医院眼科中心 吴仁毅 青光眼治疗与眼表异常 Increased Prevalence of Ocular Surface Disease Symptoms in Glaucoma Patients Using IOP-Lowering Medications D.G. Godfrey， et al. Presented at ARVO 2008 Prospective, multi-center, single-visit, survey based study 630 patients using one or more topical IOP-lowering medications Prevalence of OSD symptoms: 48.4% ODS index , mild, moderate, severe Significant differences between 1 and 2 ,1 and 3 medications No statistical difference between 2 and 3 medications  固定复方制剂 (Fixed Combinations) Cosopt ? Dorzolamide/Timolol Combigan ? Brimonidine/Timolol Xalacom Latanoprost/Timolol Duotrav Travoprost/Timolol Ganfort Bimatoprost/Timolol 应用固定复方制剂 的理由 增加患者用药依从性 约50％的患者需应用2种或更多滴眼液使眼压降低20％ 减少洗脱效应 用药间隔5分钟 减少防腐剂相关的副作用 乙酸阿奈可他(Anacortave Acetate, AA) Control of IOP in Open-Angle Glaucoma by Anecortave Acetate: A Comparison of Three Doses and Vehicle. E.R. Craven, et al Presented at ARVO 2008 Anterior Juxtascleral Depot of Anecortave Acetate: Intraocular Pressure Reduction in Different Types of Glaucoma. T.S. Prata, et al. Presented at ARVO 2008 乙酸阿奈可他(Anacortave Acetate, AA) Control of IOP in Open-Angle Glaucoma by Anecortave Acetate: A Comparison of Three Doses and Vehicle. E.R. Craven, et al Presented at ARVO 2008 Randomized double-masked multi-center (N=10) study 86 patients , IOP 24-36 mmHg A single 0.5 mL AJD of AA (3, 15, or 30 mg) or vehicle in the “worse” eye. The fellow, non-injected eye was treated with latanoprost. IOP Success Rate (3 Mon): 30mg =50%, 15 3 mg =30%, vehicle= 24% 乙酸阿奈可他(Anacortave Acetate, AA) Anterior Juxtascleral Depot of Anecortave Acetate: Intraocular Pressure Reduction in Different Types of Glaucoma. T.S. Prata, et al. Presented at ARVO 2008 Prospective, non-randomized open-labeled, 25 uncontrolled glaucoma patients. Baseline IOP : 30.9 mmHg A single AJD of AA (30 mg) in the selected eye